株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の非侵襲出生前検査・新生児スクリーニング市場:2017〜2027年

Global Non-Invasive Prenatal Testing and Newborn Screening Market, 2017-2027

発行 ROOTS ANALYSIS 商品コード 516634
出版日 ページ情報 英文 425 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=111.74円で換算しております。
Back to Top
世界の非侵襲出生前検査・新生児スクリーニング市場:2017〜2027年 Global Non-Invasive Prenatal Testing and Newborn Screening Market, 2017-2027
出版日: 2017年06月09日 ページ情報: 英文 425 Pages
概要

当レポートは、世界の非侵襲出生前検査・新生児スクリーニング市場について調査し、NIPT (非侵襲出生前検査) の全体的な情勢、様々な非侵襲技術プラットフォーに関する詳細な議論と分析、および主要企業のプロファイル、新生児スクリーニング検査の全体的な情勢、主要企業のプロファイル、およびスクリーニングタイプ・プラットフォーム別による分析、現在の規制情勢に関する詳細な議論、最新の提携動向などについて、提供しています。

第1章 序論

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 本章の概要
  • 疾患検出の重要性:スクリーニング vs. 診断
  • 遺伝的異常:イントロダクション
  • 遺伝子検査:出生前・新生児ケアにおける重要性
  • 新生児遺伝子検査:詳細な概要
    • 従来の出生前検査手法
    • 非侵襲出生前検査 (NIPT)
  • 新生児スクリーニングのコンセプト
  • 出生前検査・新生児スクリーニングに関連した倫理上の問題

第4章 非侵襲癌スクリーニング・診断のコンセプト

  • 本章の概要
  • NIPT:発展状況
  • NIPT:技術プラットフォーム
  • 出生前検査:その他のイニシアチブ
  • 新生児スクリーニング:発展状況
  • 新生児スクリーニング:その他のイニシアチブ

第5章 NIPT・新生児スクリーニング:主な考察

  • 本章の概要
  • NIPT:地域別の分布
  • NIPTの商業化:臨床効率の競合ヒートマップ分析
  • NIPT
  • NIPT:産業企業の地域分布
  • 新生児スクリーニンググリッド分析:スクリーニング種類・技術プラットフォーム別の分布
  • 新生児スクリーニングのディベロッパー情勢:企業規模・地域別の分布

第6章 出生前検査:NIPTへのフォーカス

  • 本章の概要
  • NIPTの登場
  • NIPTの主要企業:企業プロファイル
  • 一般的なNIPT:詳細な比較
  • NIPT:規制状況
  • NIPT:将来の展望

第7章 新生児スクリーニング:詳細展望

  • 本章の概要
  • 新生児スクリーニング:イントロダクション・分類
  • 新生児スクリーニングの技術進歩
  • 新生児スクリーニングの主要企業:企業プロファイル
  • 新生児スクリーニングプログラム:企業イニシアチブ
  • 新生児スクリーニング:将来の展望

第8章 その他の関連検査・サービス

  • 本章の概要
  • 保因者検査/プレコンセプションケア
  • 着床前診断 (PGD) / スクリーニング (PGD/PGS)
  • 遺伝子カウンセリング・DTC遺伝子検査サービス

第9章 近年のコラボレーション

  • 本章の概要
  • 提携モデル
  • NIPT:近年のコラボレーション
  • 新生児スクリーニング:近年のコラボレーション

第10章 NIPT・新生児スクリーニング:市場規模・予測

  • 本章の概要
  • NIPT:範囲・予測手法
  • NIPT:予測の前提条件
  • NIPT:予測
  • 新生児スクリーニング:機会分析

第11章 結論

  • 出生前検査・新生児スクリーニングは胎児・新生児の遺伝的異常を特定する一般的な診断ツールとして登場
  • 継続的なイノベーションがNIPT・先進新生児スクリーニング検査の発展を導く
  • これらの新たなスクリーニング手法が広範な疾患検出に応える
  • 様々な地域にわたって複数の新興企業が存在することによる関心の着実な高まり
  • 提携数の増加は収益性の高い将来の可能性を暗示
  • 新興諸国における倫理的な問題にも関わらず、NIPT市場は長期的に大きく繁栄する見込み
  • 新生児スクリーニング市場は依然として先進技術によって発展すると同時に、NIPT診断市場は既に成長加速を示す

第12章 インタビュー記録

第13章 調査分析

第14章 付録1:表形式データ

第15章 付録2:企業・組織リスト

図表

目次
Product Code: RA10083

It has been estimated that close to 131 million babies are born each year across the globe. Of these, approximately 7.9 million are born with birth defects. In fact, more than 7,000 genetic disorders have been identified so far and the number is rising.Genetic testing solutions that enable early detection of genetic abnormalities in fetuses and newborns are important to ensure that the person does not face complications later in life. With the emergence of innovative diagnostic and screening techniques, several methods of genetic testing have become popular. These include carrier testing, preimplantation genetic diagnosis / screening (PGD / PGS), prenatal testing, paternity testing and newborn screening. Amongst these, prenatal testing (primarily Non-invasive prenatal testing (NIPT)) and newborn screening have gained relatively more traction in prenatal and neonatal care.

Specifically, NIPT has emerged as an efficient screening method in prenatal care that can analyze the cell-free DNA (cfDNA) extracted from maternal blood sample during pregnancy. NIPTs offer several advantages over conventional prenatal testing procedures; in addition to being non-invasive, these tests offer shorter turnaround times and high accuracy. It has been reported that the increasing popularity of NIPTs has led to a 50% decline in the use of invasive prenatal testing procedures (such as amniocentesis and chorionic villus sampling (CVS)). With the changing mindset of people belonging to different cultural and socio-economic background, the uptake of NIPTs is likely to increase further. Moreover, with the rising awareness and availability of NIPTs designed for a wide array of disease indications, and development of innovative and versatile technologies, we expect that the interest will continue to grow.

Within neonatal care, the emergence of advanced technologies in this domain has reflected a gradual rise in the overall development of advanced newborn screening tests in the last few years. In fact, public service bodies in more than 70 countries across the globe have facilitated the establishment of newborn screening programs in their respective countries. With an already established platform, we expect the overall newborn screening market to continue its gradual rise driven by higher adoption, competitive prices and availability of these tests in various geographies across the globe.

Synopsis:

The “Global Non-Invasive Prenatal Testing and Newborn Screening Market, 2017-2027” report features an extensive study on the current market landscape of non-invasive prenatal testing (NIPT) and newborn screening diagnostics that are commercially available or are under development. NIPT and newborn screening tests are designed for the detection of different types of genetic abnormalities in fetuses and newborns. Detection of genetic disorders in prenatal and neonatal stages is critical tolower the child mortality rates. Moreover, early detection, treatment and management of these genetic disorders is important to avoid serious health problems at later stages in life. The study offers a comprehensive discussion on the future potential of these tests in prenatal and neonatal care.

Ever since the launch and subsequent success of the first NIPT, the NIFTY® test (launched by BGI in August 2011), several firms have taken initiatives to develop and commercialize NIPTs. Currently, a number of NIPTs that are designed to screen for conditions such as chromosomal abnormalities, sex chromosomal abnormalities and microdeletion syndromes are available in the market.In addition, many companies have entered into collaborations to distribute these tests across various geographies in order to expand the availability to a wider population. Examples of popular NIPT tests include Harmony® test (Ariosa Diagnostics, acquired by Roche), PraenaTest® / PrenaTest® (LifeCodexx, a subsidiary of GATC Biotech), Panorama® (Natera®), NIFTY® (BGI), Verifi® (Verinata Health, acquired by Illumina®), VisibiliTTM (SequenomTM, acquired by LabCorp®) and IONA® test / Safe NIPT (Premaitha Health).

The advent of routine newborn screening in the 1960s for the detection of phenylketonuria (PKU) established the role and importance of newborn screening in mitigating disorders in newborns. The field is continuously evolving as the awareness related to benefits of newborn screening increases. Moreover, introduction of advanced technologies such as next-generation sequencing (NGS) and tandem mass spectroscopy has notably accelerated the development in this domain. Newborn screening diagnostics are primarily available for conditions such as metabolic disorders, endocrine disorders, hemoglobin disorders, congenital heart disorders and hearing disorders.

Both prenatal testing and newborn screening offer several benefits in terms of disease management in neonatal care and has gathered interest from a wide range of companies worldwide. In total, we have identified 76 NIPT tests and 38 advanced newborn screening tests. In addition, there are several companies that are engaged in the development of basic tests, devices, systems and technology platforms for both prenatal testing and newborn screening. One of the key objectives of this report was to understand the current activity and the future potential of the NIPT and newborn screening markets. Amongst other elements, the report covers the following:

NIPT:

  • The overall landscape of NIPT tests with respect to the stage of development, sample type, technology platforms, type of indications, stage of pregnancy and result turnaround time. In addition, the report provides a detailed discussion and analysis on the various innovative technology platforms available for the development of NIPTs and the indications screened.
  • Comprehensive profiles of the leading players in the field of NIPT and their products, highlighting details of the company, financial and funding information (if available), product portfolio and a comprehensive future outlook. Likewise, the product profiles provide information on the product and their development history, technology platforms, test procedure, specifications, advantages and clinical information (if available).
  • An elaborate geographical coverage analysis of the NIPT tests available / under development across the globe, a comparative heat map analysis of NIPTs (on the basis of sensitivity, specificity, result turnaround time and stage of pregnancy when the test can be performed), harvey ball analysis highlighting the panel strength of each test based on the number of indications being screened, and the geographical distribution of the companies involved in the development of NIPTs.

Newborn Screening:

  • The overall landscape of newborn screening tests with respect to the stage of development, screening type, technology platform, type of indication, period of sample collection after birth and result turnaround time.
  • Detailed profiles of the players involved in the field of newborn screening and their products highlighting details on the company, financial and funding information (if available), product portfolio and a comprehensive future outlook. Likewise, the product profiles provide information on the product specifications and test methodology. In addition, the report includes a comprehensive list of the core and secondary disorders / deficiencies recommended for newborn screening.
  • An illustrative grid representation of the newborn screening tests based on screening type (basic newborn screening, expanded newborn screening, comprehensive newborn screening and advanced newborn screening) and technology platform, and an overview of the landscape of industry developers (start-ups, mid-sized and large-sized players).

Additionally, the report includes:

  • A detailed discussion of the existing regulatory landscape in the field of NIPT and the current status of the government mandated newborn screening programs established in various countries across the globe to provide proper medical care to newborns.
  • Partnerships that have been recently been inked amongst different stakeholders, covering product distribution / marketing agreements, development / commercialization agreements and mergers / acquisitions.
  • A detailed survey analysis primarily focused on gaining additional insights on the company's tests or services, highlighting the focus area of the company, type of the products, purpose and commercial availability of the lead product(s).

The study features a detailed analysis on the existing size and future growth opportunities (2017-2027) in the NIPT and newborn screening markets. We have provided insights on the likely regional evolution of the NIPT market across patients in three risk group segments (high risk, average risk and low risk) covering North America (the US, Canada and Mexico), Europe (France, Germany, Italy, Spain, the UK and rest of Europe) Asia (Japan, China and India) and rest of the world. In addition, we have provided the likely distribution by type of indications, stage of pregnancy when the test can be conducted and the share of individual NIPTs. The forecast takes into account the impending price variations that are likely to emerge in the mid-long term as a result of growing adoption and increased competition. In order to account for uncertainties associated with some of the key parameters and to add robustness to our model, we have presented three different forecast scenarios, depicting conservative, base and optimistic tracks of the market's evolution.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data and primary research discussions. For the purpose of the study, we invited over 150 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities, challenges and likely future trends. The opinions and insights presented in this study were also influenced by discussions conducted with experts in this field. These include contributions from Jim Patterson (Vice President, Sales and Marketing North America, EvolveGene®), Osama Fikry (Metabolic and Diagnostic Head, NewBridge Pharmaceuticals) and Silke Arndt (Medical Scientist and NGS Manager, Inqaba Biotec).All financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights:

  • 1. During our research, we identified 76 NIPTs; of the commercially available tests, majority are laboratory-developed tests while only a few are CE-IVD certified. The CE-IVD marked tests include Clarigo® (Multiplicom), Harmony® test (Ariosa Diagnostics, acquired by Roche), IONA® test (Premaitha Health), Prenatal BACs-on-BeadsTM (PerkinElmer®), PraenaTest® / PrenaTest® (LifeCodexx, a subsidiary of GATC Biotech), Prendia (Genesupport, FASTERIS, Swiss Institute for Bioinformatics), SerenityTM test (Genesis GeneticsTM) and Tranquility (Genoma, a subsidiary of ESPERITE).
  • 2. Of the total NIPTs (commercially available / under development), 83% are designed on the basis of massively parallel sequencing / next-generation sequencing methods (MPS / NGS) for the detection of diseases under their test panels. It is worth highlighting that some developers are utilizing a novel epigenetics based approach for the development of their NIPTs.
  • 3. The current market landscape features contributions from big pharmaceutical companies and small to mid-sized players. Established players engaged in the development of NIPTsinclude (in alphabetical order) BGI, Natera®, PerkinElmer®, SequenomTM (acquired by LabCorp®), Sonic Healthcare and Quest DiagnosticsTM. Small and mid-sized companies engaged in the field of NIPT include (in alphabetical order) Ariosa Diagnostics (acquired by Roche), Berry Genomics, EvolveGene, LifeCodexx (a subsidiary of GATC Biotech), NIPD Genetics, NxGen MDx, Premaitha Health and Verinata Health (acquired by Illumina®).
  • 4. Prominent academic institutions and universities involved in the field of NIPT include (in alphabetical order) the Birmingham Women's Hospital, Cyprus Institute of Neurology and Genetics, Murdoch Children's Research Institute, National University of Singapore, Stanford University, Swiss Institute for Bioinformatics, The Chinese University ofHong Kong and University of Antwerp.
  • 5. We also came across 38 advanced newborn screening tests available for the detection ofa large number of disorders / deficiencies including metabolic disorders, endocrine disorders, hemoglobin disorders, congenital heart disorders and hearing disorders. Of the total advanced newborn screening tests, 66% of the tests use blood as the testing sample (categorized as basic screening tests). This is followed by advanced screening tests and comprehensive screening tests capturing a share of 16% and 10%, respectively. Nearly 8% of the newborn screening tests utilize urine as the sample and are categorized as expanded newborn screening tests.
  • 6. Over 135 collaborations have been inked in the field of NIPT between 2011 and 2017. Although a significant proportion of these agreements focus on distribution / marketing of NIPTs to expand their access and coverage in different geographies (54%), we came across a number of product development / commercialization agreements (15%), merger / acquisition agreements (9%) and product / technology licensing agreements (8%). Several companies have entered into multiple collaborations; these include SequenomTM (24 agreements), Natera® (20 agreements), Premaitha Health (19 agreements), BGI (18 agreements), Ariosa Diagnostics (14 agreements) and Illumina® (13 agreements).
  • 7. The NIPT market, primarily driven by increasing awareness and adoption of NIPTs, is anticipated to grow at an annualized rate of 15% between 2017 and 2027. The current market is dominated by the tests offered to expectant women belonging to high risk category, capturing 52% market share. However, by 2027, the average risk market is likely to be amongst the key drivers; we expect its share to grow from 37% in 2017 to 45% by 2027.
  • 8. Amongst specific indications screened under NIPT test panels, chromosomal abnormalities (primarily including trisomy 21 (Down syndrome), trisomy 18 (Edward syndrome), trisomy 13 (Patau syndrome))are likely to capture the largest share of the market in both 2017 (44%) and 2027 (56%). This is followed by sex chromosomal abnormalities, capturing a share of 24% in 2017 and 28% in 2027. These include Turner syndrome, Klinefelter syndrome, Triple X syndrome and Jacob syndrome. Microdeletion syndromes, primarily including Cri-du-chat syndrome, DiGeorge syndrome, Prader-Willi syndrome, monosomy 1p36 and Wolf-Hirschhorn syndrome, are likely to account for a share of 22% in 2017 and 14% in 2027.
  • 9. With regard to the geographical activity, in 2017, the North America is likely to capture the maximum share (37%) followed by Europe (35%) and Asia (24%). Over the coming decade, Asian regions are likely to drive the growth resulting in a share of 29% in 2027. It is important to highlight that, within Asia, countries such as China, India, Japan, have several developers and distributors of NIPT tests, demonstrating an increasing interest in these regions.

Research Methodology:

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct extensive secondary research as well as interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market may evolve across different regions and sub-segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various sources of information.

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high level view on the current state of the NIPT and the newborn screening market and its likely evolution over the next decade.

Chapter 3 provides a general introduction of various types of chromosomal abnormalities and genetic disorders occurring in fetuses and newborns with information on their statistics, and the different types of genetic tests available for their detection. It outlines the concept of invasive and non-invasive prenatal testing. In addition, the chapter offers a discussion on the historical evolution of newborn screening.

Chapter 4 provides a holistic view of the NIPT and newborn screening market. It provides a comprehensive list of NIPT and newborn screening tests. The chapter includes a detailed analysis of the NIPTs based on the development stage, technology platforms, type of indications tested, stage of pregnancy and result turnaround time. In addition, it includes a detailed analysis of the newborn screening tests based on the screening type, technology platform, type of indication, period of sample collection after birth and result turnaround time. The chapter also lists the basic prenatal testing and newborn screening tests, devices, systems and technology platforms.

Chapter 5 is a compilation of key insights gained from this study. It includes a geographical coverage analysis that highlights the availability of each NIPT test in different regions across the globe, and a heat map representing the relative clinical performance of the commercially available NIPTs on the basis of sensitivity, specificity, result turnaround time and the stage of pregnancy when the test can be performed. In addition, it presents a Harvey ball analysis depicting the test panel strength on the basis of number of indications screened, and a world map to represent the geographical presence and the activity of companies involved in the field of NIPT. The chapter also includes a grid representation of the newborn screening tests, highlighting the distribution of these tests on the basis of screening type (basic newborn screening, expanded newborn screening, comprehensive newborn screening and advanced newborn screening) and the technology platforms used to design them. Additionally, it features a developer landscape of the companies involved in the field of newborn screening, distributed on the basis of the company size and geographical presence.

Chapter 6 offers a comprehensive discussion on NIPT tests, highlighting advantages and challenges associated with the development and use of these tests. The chapter features detailed company profiles of the leading players that are involved in the development of NIPT tests. Each profile includes a brief overview of the company, its financial information, funding details, product portfolio and an informed future outlook. It also includes detailed profiles of the products of these key players. Each product profile provides information on the development history, specifications, technology platform, procedure, advantages and clinical information of different products offered by the company. In addition, the chapter includes a development timeline marking the launch of the popular NIPT tests between 2011 and 2016. It also provides a commercial landscape of the most popular NIPTs on the basis of different characteristics of these tests.

Chapter 7 offers a comprehensive discussion on newborn screening. It talks about different types of next-generation newborn screening procedures. We have provided company profiles and product profiles of the key players engaged in the development of newborn screening tests. In addition, it includes brief profiles of other players involved in this field. The section also includes an elaborate discussion on the current spread of newborn screening programs established in various countries across the globe to provide proper medical care to newborns.

Chapter 8 provides details on the other diagnostic tests / services available for genetic testing in newborns and fetuses; these include carrier testing / preconception care, preimplantation genetic testing (PGT) (preimplantation genetic diagnosis / screening (PGD / PGS)), genetic counselling and direct to consumer (DTC) genetic testing services. We have provided a brief overview of these tests / services, highlighting their general procedure / workflow, indications being evaluated and their indicative development pipeline.

Chapter 9 features an elaborate discussion on the collaborations and partnerships that have been inked amongst players in both NIPT and newborn screening markets. We have also discussed the various partnership models that have been implemented, highlighting the most common forms of deals / agreements in this domain.

Chapter 10 highlights the market forecast and sizing of the overall NIPT and newborn screening markets. This chapter discusses, in detail, the parameters that are likely to influence the evolution of these markets. It features detailed insights on the likely evolution of the NIPT market for different patient risk group segments (high risk, average risk and low risk). The chapter highlights the likely distribution of the market across North America (US, Canada and Mexico), Europe (France, Germany, Italy, Spain, the UK and rest of Europe), Asia (Japan, China and India) and rest of the world. It also presents a detailed market segmentation by the key indications, stage of pregnancy when the tests can be performed and share of individual NIPT tests. In addition, the chapter offers a high-level view on the upcoming newborn screening market across the globe.

Chapter 11 summarizes the overall report and provides a recap of the key takeaways from the study. It also presents our independent opinion on the future of both NIPT and newborn screening market based on the research and analysis described in the previous chapters.

Chapter 12 is a collection of interview transcripts of the discussions held with key stakeholders in these fields.We have presented the insights provided to us by Jim Patterson (Vice President, Sales and Marketing North America, EvolveGene®),Osama Fikry (Metabolic and Diagnostic Head, NewBridge Pharmaceuticals) and Silke Arndt (Medical Scientist and NGS Manager, Inqaba Biotec).

Chapter 13 illustrates a detailed analysis on the survey conducted for gaining a deeper understanding on the nature of products and services offered by the companies involved in NIPT and / or newborn screening fields.

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Importance of Disease Detection: Screening Versus Diagnosis
  • 3.3. Genetic Abnormalities: An Introduction
    • 3.3.1. Classification of Genetic Disorders
      • 3.3.1.1. Chromosomal Abnormalities
      • 3.3.1.2. Single Gene Disorders
      • 3.3.1.3. Teratogenic Problems
      • 3.3.1.4. Complex / Multifactorial Problems
    • 3.3.2. Statistics and Epidemiology of Genetic Disorders
    • 3.3.3. Common Genetic Disorders: Causes and Symptoms
  • 3.4. Genetic Tests: Importance in Prenatal and Neonatal Care
  • 3.5. Prenatal Genetic Testing: A Detailed Overview
    • 3.5.1. Conventional Methods of Prenatal Testing
      • 3.5.1.1. Maternal Serum Screening
      • 3.5.1.2. Ultrasonography
      • 3.5.1.3. Invasive Confirmatory Tests
        • 3.5.1.3.1. Amniocentesis
        • 3.5.1.3.2. Chorionic Villus Sampling (CVS)
      • 3.5.1.4. Fetal Cells in Maternal Blood (FCMB)
    • 3.5.2. Non-Invasive Prenatal Testing (NIPT)
  • 3.6. The Concept of Newborn Screening
    • 3.6.1. Evolution of Newborn Screening
  • 3.7. Ethical Issues Related to Prenatal Testing and Newborn Screening

4. NIPT AND NEWBORN SCREENING: MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. NIPT: Development Landscape
    • 4.2.1. NIPT: Distribution by Stage of Development
    • 4.2.2. NIPT: Distribution by Technology Platforms
    • 4.2.3. NIPT: Distribution by Type of Indication
    • 4.2.4. NIPT: Distribution by Stage of Pregnancy
    • 4.2.5. NIPT: Distribution by Result Turnaround Time
  • 4.3. NIPT: Technology Platforms
  • 4.4. Prenatal Testing: Other Initiatives
  • 4.5. Newborn Screening: Development Landscape
    • 4.5.1. Newborn Screening: Distribution by Screening Type
    • 4.5.2. Newborn Screening: Distribution by Technology Platforms
    • 4.5.3. Newborn Screening: Distribution by Type of Indication
    • 4.5.4. Newborn Screening: Distribution by Period of Sample Collection After Birth
    • 4.5.5. Newborn Screening: Distribution by Result Turnaround Time
  • 4.6. Newborn Screening: Other Initiatives

5. NIPT AND NEWBORN SCREENING: KEY INSIGHTS

  • 5.1. Chapter Overview
  • 5.2. NIPTs: Distribution by Geographical Coverage
  • 5.3. Commercialized NIPTs: A Competitive Heat Map Analysis for Clinical Efficiency
  • 5.4. NIPTs: Harvey Ball Analysis for Test Panel Strength
  • 5.5. NIPTs: Geographical Distribution of Industry Players
  • 5.6. Newborn Screening Grid Analysis: Distribution by Screening Type and Technology Platforms
  • 5.7. Newborn Screening Developer Landscape: Distribution by Company Size and Geography

6. PRENATAL TESTING: FOCUS ON NIPT

  • 6.1. Chapter Overview
  • 6.2. Emergence of NIPT
  • 6.3. NIPT Key Players: Company Profiles
    • 6.3.1. Ariosa Diagnostics (Acquired by Roche)
      • 6.3.1.1. Company Introduction
      • 6.3.1.2. Financial Information
      • 6.3.1.3. Product Portfolio
        • 6.3.1.3.1. Harmony® Test
          • 6.3.1.3.1.1. Product Overview and Development History
          • 6.3.1.3.1.2. Product Specifications
          • 6.3.1.3.1.3. Technology Overview
          • 6.3.1.3.1.4. Procedure and Interpretation of Results
          • 6.3.1.3.1.5. Advantages
          • 6.3.1.3.1.6. Clinical Information
      • 6.3.1.4. Future Outlook
    • 6.3.2. BGI
      • 6.3.2.1. Company Introduction
      • 6.3.2.2. Financial Information
      • 6.3.2.3. Product Portfolio
        • 6.3.2.3.1. NIFTY® Test
          • 6.3.2.3.1.1. Product Overview and Development History
          • 6.3.2.3.1.2. Product Specifications
          • 6.3.2.3.1.3. Technology Overview
          • 6.3.2.3.1.4. Procedure and Interpretation of Results
          • 6.3.2.3.1.5. Advantages
          • 6.3.2.3.1.6. Clinical Information
      • 6.3.2.4. Future Outlook
    • 6.3.3. Natera®
      • 6.3.3.1. Company Introduction
      • 6.3.3.2. Financial Information
      • 6.3.3.3. Product Portfolio
        • 6.3.3.3.1. Panorama® Test
          • 6.3.3.3.1.1. Product Overview and Development History
          • 6.3.3.3.1.2. Product Specifications
          • 6.3.3.3.1.3. Technology Overview
          • 6.3.3.3.1.4. Procedure and Interpretation of Results
          • 6.3.3.3.1.5. Advantages
          • 6.3.3.3.1.6. Clinical Information
      • 6.3.3.4. Future Outlook
    • 6.3.4. SequenomTM (Acquired by LabCorp®)
      • 6.3.4.1. Company Introduction
      • 6.3.4.2. Financial Information
      • 6.3.4.3. Product Portfolio
        • 6.3.4.3.1. MaterniT® GENOME
          • 6.3.4.3.1.1. Product Overview and Development History
          • 6.3.4.3.1.2. Product Specifications
          • 6.3.4.3.1.3. Procedure and Interpretation of Results
          • 6.3.4.3.1.4. Advantages
          • 6.3.4.3.1.5. Clinical Information
        • 6.3.4.3.2. VisibiliTTM Test
          • 6.3.4.3.2.1. Product Overview and Development History
          • 6.3.4.3.2.2. Product Specifications
          • 6.3.4.3.2.3. Procedure and Interpretation of Results
          • 6.3.4.3.2.4. Advantages
          • 6.3.4.3.2.5. Clinical Information
        • 6.3.4.3.3. MaterniT21® PLUS Test
          • 6.3.4.3.3.1. Product Overview and Development History
          • 6.3.4.3.3.2. Product Specifications
          • 6.3.4.3.3.3. Technology Overview
          • 6.3.4.3.3.4. Procedure and Interpretation of Results
          • 6.3.4.3.3.5. Advantages
          • 6.3.4.3.3.6. Clinical Information
        • 6.3.4.3.4. SensiGene® RhD Test
          • 6.3.4.3.4.1. Product Overview and Development History
            • 6.3.4.3.4.2. Product Specifications
            • 6.3.4.3.4.3. Technology Overview
            • 6.3.4.3.4.4. Procedure and Interpretation of Results
            • 6.3.4.3.4.5. Advantages
            • 6.3.4.3.4.6. Clinical Information
          • 6.3.4.3.5. NextViewTM Array Diagnostic Test Platform
            • 6.3.4.3.5.1. Product Overview and Development History
            • 6.3.4.3.5.2. Product Specifications
      • 6.3.4.4. Future Outlook
    • 6.3.5. Verinata Health (Acquired by Illumina®)
      • 6.3.5.1. Company Introduction
      • 6.3.5.2. Financial Information
      • 6.3.5.3. Product Portfolio
        • 6.3.5.3.1. Verifi® Prenatal Test / InformaSeqSM
          • 6.3.5.3.1.1. Product Overview and Development History
          • 6.3.5.3.1.2. Product Specifications
          • 6.3.5.3.1.3. Technology Overview
          • 6.3.5.3.1.4. Procedure and Interpretation of Results
          • 6.3.5.3.1.5. Advantages
          • 6.3.5.3.1.6. Clinical Information
      • 6.3.5.4. Future Outlook
  • 6.4. Popular NIPTs: A Detailed Comparison
  • 6.5. NIPT: Regulatory Landscape
  • 6.6. NIPT: Future Outlook

7. NEWBORN SCREENING: DETAILED OUTLOOK

  • 7.1. Chapter Overview
  • 7.2. Newborn Screening: Introduction and Classification
    • 7.2.1. Classification of Newborn Screening Tests: By Sample Type
    • 7.2.2. Classification of Newborn Screening Tests: By Period of Sample Collection After Birth
    • 7.2.3. Classification of Newborn Screening: By Patient Risk Group
  • 7.3. Technological Advances in Newborn Screening
  • 7.4. Newborn Screening Key Players: Company Profiles
    • 7.4.1. BGI
      • 7.4.1.1. Company Introduction
      • 7.4.1.2. Financial Information
      • 7.4.1.3. Product Portfolio
        • 7.4.1.3.1. NOVATM Newborn Genetic Test
          • 7.4.1.3.1.1. Product Overview
          • 7.4.1.3.1.2. Product Specifications and Test Methodology
        • 7.4.1.3.2. NOVATM Metabolic Disease Screening
          • 7.4.1.3.2.1. Product Overview
          • 7.4.1.3.2.2. Product Specifications and Test Methodology
      • 7.4.1.4. Future Outlook
    • 7.4.2. Cordlife Group
      • 7.4.2.1. Company Introduction
      • 7.4.2.2. Financial Information
      • 7.4.2.3. Product Portfolio
        • 7.4.2.3.1. MetaScreenTM
          • 7.4.2.3.1.1. Product Overview
          • 7.4.2.3.1.2. Product Specifications and Test Methodology
      • 7.4.2.4. Future Outlook
    • 7.4.3. Genomi-k
      • 7.4.3.1. Company Introduction
      • 7.4.3.2. Product Portfolio
        • 7.4.3.2.1. Audi-k® Service
          • 7.4.3.2.1.1. Product Overview
          • 7.4.3.2.1.2. Product Specifications and Test Methodology
        • 7.4.3.2.2. Cardi-k® Service
          • 7.4.3.2.2.1. Product Overview
          • 7.4.3.2.2.2. Product Specifications and Test Methodology
        • 7.4.3.2.3. Tami-k® Service
          • 7.4.3.2.3.1. Product Overview
          • 7.4.3.2.3.2. Product Specifications and Test Methodology
    • 7.4.4. Genetadi Biotech
      • 7.4.4.1. Company Introduction
      • 7.4.4.2. Product Portfolio
        • 7.4.4.2.1. Neonatal-One Plus
          • 7.4.4.2.1.1. Product Overview
          • 7.4.4.2.1.2. Product Specifications and Test Methodology
      • 7.4.4.3. Future Outlook
    • 7.4.5. NextlineTM Diagnostics
      • 7.4.5.1. Company Introduction
      • 7.4.5.2. Product Portfolio
        • 7.4.5.2.1. BIRTHRIGHT
          • 7.4.5.2.1.1. Product Overview
          • 7.4.5.2.1.2. Product Specifications and Test Methodology
      • 7.4.5.3. Future Outlook
    • 7.4.6. Parabase Genomics
      • 7.4.6.1. Company Introduction
      • 7.4.6.2. Financial Information
      • 7.4.6.3. Product Portfolio
        • 7.4.6.3.1. NewbornDxTM Test
          • 7.4.6.3.1.1. Product Overview
          • 7.4.6.3.1.2. Product Specifications and Test Methodology
        • 7.4.6.3.2. NewbornDxTM HL
          • 7.4.6.3.2.1. Product Overview
          • 7.4.6.3.2.2. Product Specifications and Test Methodology
      • 7.4.6.4. Future Outlook
    • 7.4.7. PerkinElmer® Genetics
      • 7.4.7.1. Company Introduction
      • 7.4.7.2. Financial Information
      • 7.4.7.3. Product Portfolio
        • 7.4.7.3.1. StepOne® Newborn Screening Panel
          • 7.4.7.3.1.1. Product Overview
          • 7.4.7.3.1.2. Product Specifications and Test Methodology
      • 7.4.7.4. Future Outlook
    • 7.4.8. SouthGenetics
      • 7.4.8.1. Company Introduction
      • 7.4.8.2. Product Portfolio
        • 7.4.8.2.1. BabyGenesTM
          • 7.4.8.2.1.1. Product Overview
          • 7.4.8.2.1.2. Product Specifications and Test Methodology
      • 7.4.8.3. Future Outlook
    • 7.4.9. Other Prominent Players
      • 7.4.9.1. AB SCIEX
      • 7.4.9.2. Aegis Sciences
      • 7.4.9.3. ARCHIMEDlife
      • 7.4.9.4. Baby Genes
      • 7.4.9.5. CENTOGENE
      • 7.4.9.6. EGL Genetic Diagnostics
      • 7.4.9.7. GeneTech
      • 7.4.9.8. iLife Discoveries
      • 7.4.9.9. Macrogen
      • 7.4.9.10. MapmygenomeTM
      • 7.4.9.11. Navigene Genetic Science
      • 7.4.9.12. NeoGen Labs
      • 7.4.9.13. Next Biosciences
      • 7.4.9.14. NIMGenetics
      • 7.4.9.15. Pediatrix Medical Group
      • 7.4.9.16. PreventiNe Life Care
      • 7.4.9.17. Synapse Diagnostics
      • 7.4.9.18. Trivitron Healthcare
  • 7.5. Newborn Screening Programs: Government Initiatives
    • 7.5.1. Asia Pacific
    • 7.5.2. Europe
    • 7.5.3. Latin America
    • 7.5.4. Middle East and North Africa (MENA)
    • 7.5.5. North America
  • 7.6. Newborn Screening: Future Outlook

8. OTHER ASSOCIATED TESTS AND SERVICES

  • 8.1. Chapter Overview
  • 8.2. Carrier Testing / Preconception Care
    • 8.2.1. Carrier Testing / Preconception Care: An Overview
    • 8.2.2. Carrier Testing / Preconception Care: Commercialized Tests
  • 8.3. Preimplantation Genetic Diagnosis / Screening (PGD / PGS)
    • 8.3.1. PGD / PGS: An Overview
    • 8.3.2. PGD / PGS: Commercialized Tests
  • 8.4. Genetic Counseling and Direct to Customer (DTC) Genetic Testing Services

9. RECENT COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. NIPT: Recent Collaborations
    • 9.3.1. Recent Collaborations: Distribution by Year
    • 9.3.2. Recent Collaborations: Distribution by Type of Model
    • 9.3.3. Recent Collaborations: Most Active Companies
  • 9.4. Newborn Screening: Recent Collaborations
    • 9.4.1. Recent Collaborations: Distribution by Year
    • 9.4.2. Recent Collaborations: Distribution by Type of Model
    • 9.4.3. Recent Collaborations: Most Active Companies

10. NIPT AND NEWBORN SCREENING: MARKET SIZING AND FORECAST

  • 10.1. Chapter Overview
  • 10.2. NIPT: Scope and Forecast Methodology
  • 10.3. NIPT: Forecast Assumptions
  • 10.3.1. Patient Population
  • 10.3.2. Price of Test
  • 10.3.3. Adoption / Penetration Rate
  • 10.4. NIPT: Forecast Projections, 2017-2027
    • 10.4.1. NIPT Market, 2017-2027
    • 10.4.2. NIPT Market: Distribution by Patient Risk Group
    • 10.4.3. NIPT Market: Distribution by Geography
      • 10.4.3.1. NIPT Market in North America
      • 10.4.3.2. NIPT Market in Europe
      • 10.4.3.3. NIPT Market in Asia
      • 10.4.3.4. NIPT Market in Rest of the World
    • 10.4.4. NIPT Market: Distribution by Indication
    • 10.4.5. NIPT Market: Distribution by Stage of Pregnancy
    • 10.4.6. NIPT Market: Distribution by Share of Individual NIPTs
  • 10.5. Newborn Screening: Opportunity Analysis

11. CONCLUSION

  • 11.1. Prenatal Testing and Newborn Screening Have Emerged as Popular Diagnostic Tools for Identification of Genetic Abnormalities in Fetuses and Newborns
  • 11.2. Continuous Innovation has Led to the Development of NIPTs and Advanced Newborn Screening Tests
  • 11.3. These Novel Screening Methods Cater to a Wide Spectrum of Disease Indications
  • 11.4. The Interest has Steadily Risen with the Presence of Multiple Start-ups Across Different Geographies
  • 11.5. The Growing Number of Partnerships are Indicative of a Lucrative Future Potential
  • 11.6. Despite the Ethical Challenges in Developing Countries, the NIPT Market is Likely to Prosper Significantly in the Long Term
  • 11.7. While the Newborn Screening Market is Still Evolving with Advanced Techniques, the NIPT Diagnostic Market is Already Witnessing an Accelerated Growth

12. INTERVIEW TRANSCRIPTS

  • 12.1. Chapter Overview
  • 12.2. Jim Patterson, Vice President, Sales and Marketing North America, EvolveGene®
  • 12.3. Osama Fikry, Metabolic and Diagnostic Head, NewBridge Pharmaceuticals
  • 12.4. Silke Arndt, Medical Scientist and NGS Manager, Inqaba Biotec

13. SURVEY ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Seniority Level of Respondents
  • 13.3. Focus Area of the Company
  • 13.4. Type of Lead Product(s)
  • 13.5. Purpose of Lead Product(s)
  • 13.6. Commercial Availability of Lead Product(s)
  • 13.7. Likely Market Size

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures:

  • Figure 3.1: Genetic Disorders: Categories
  • Figure 3.2: Chromosomal Abnormalities: Numerical and Structural Disorders
  • Figure 3.3: Genetic Disorders in Fetuses
  • Figure 3.4: Genetic Disorders in Newborns
  • Figure 3.5: Chromosomal Abnormalities: Distribution by Type
  • Figure 3.6: Common Causes of Deaths in Newborns
  • Figure 3.7: Genetic Tests in Prenatal and Neonatal Care
  • Figure 3.8: Genetic Testing: Benefits and Drawbacks
  • Figure 3.9: Reasons for Prenatal Testing
  • Figure 3.10: Evolution of Prenatal Testing
  • Figure 3.11: Conventional Prenatal Tests in Different Stages of Pregnancy
  • Figure 3.12: Maternal Serum Screening Tests: Available Options
  • Figure 3.13: Reasons to Perform Ultrasound at Various Stages in Pregnancy
  • Figure 3.14: Amniocentesis: General Procedure
  • Figure 3.15: Newborn Screening: Components
  • Figure 3.16: Newborn Screening: Key Milestones
  • Figure 4.1: NIPT: Distribution by Stage of Development
  • Figure 4.2: NIPT: Distribution by Technology Platforms
  • Figure 4.3: NIPT: Distribution by Type of Indication
  • Figure 4.4: NIPT: Distribution by Chromosomal Abnormalities
  • Figure 4.5: NIPT: Distribution by Sex Chromosomal Abnormalities
  • Figure 4.6: NIPT: Distribution by Microdeletion Syndromes
  • Figure 4.7: NIPT: Distribution by Stage of Pregnancy
  • Figure 4.8: NIPT: Distribution by Result Turnaround Time
  • Figure 4.9: Newborn Screening: Distribution by Screening Type
  • Figure 4.10: Newborn Screening: Distribution by Technology Platforms
  • Figure 4.11: Newborn Screening: Distribution by Type of Indication
  • Figure 4.12: Newborn Screening: Distribution by Period of Sample Collection After Birth
  • Figure 4.13: Newborn Screening: Distribution by Result Turnaround Time
  • Figure 5.1: NIPTs: Categorization by Heat Map Analysis
  • Figure 5.2: NIPTs: Geographical Distribution of Industry Players
  • Figure 5.3: Newborn Screening Grid Analysis: Distribution by Screening Type and Technology Platforms
  • Figure 5.4: Newborn Screening Developer Landscape: Distribution by Company Size and Geography
  • Figure 6.1: NIPTs: Key Objectives
  • Figure 6.2: NIPT Tests: Launch Timeline
  • Figure 6.3: Harmony® Test: Steps of Operation
  • Figure 6.4: BGI: Product Portfolio
  • Figure 6.5: NIFTY® Test: Key Milestones
  • Figure 6.6: NIFTY® Test: Eligible Patient Population
  • Figure 6.7: NIFTY® Test: Steps of Operation
  • Figure 6.8: Natera®: Annual Revenues, 2013-Q1 2017 (USD Million)
  • Figure 6.9: Natera®: Product Portfolio
  • Figure 6.10: Panorama® Test: Eligible Patient Population
  • Figure 6.11: Panorama® Test: Steps of Operation
  • Figure 6.12: SequenomTM: Evolution of the NIPT Portfolio
  • Figure 6.13: SequenomTM: Annual Revenues, 2011-Q1 2016 (USD Million)
  • Figure 6.14: SequenomTM: Product Portfolio
  • Figure 6.15: Verifi® Prenatal Test: Eligible Patient Population
  • Figure 6.16: Verifi® Prenatal Test: Steps of Operation
  • Figure 7.1: Newborn Screening: Modes of Operation
  • Figure 7.2: NOVATM Newborn Genetic Test: Eligible Patient Population
  • Figure 7.3: NOVATM Newborn Genetic Test: Steps of Operation
  • Figure 7.4: Cordlife Group: Annual Revenues, 2012-2016 (USD Million)
  • Figure 7.5: Cordlife Group: Product Portfolio
  • Figure 7.6: Genomi-k: Product Portfolio
  • Figure 7.7: PerkinElmer®: Annual Revenues, 2012-Q1 2017 (USD Million)
  • Figure 7.8: Newborn Screening Programs: Current Geographical Spread
  • Figure 8.1: Carrier Testing: General Procedure
  • Figure 8.2: Carrier Testing: Recessive Disorders Inheritance
  • Figure 8.3: Carrier Testing: Clinical Benefits
  • Figure 8.4: Types of Predictive Testing
  • Figure 8.5: PGD: General Procedure
  • Figure 8.6: PGD: Most Common Types of Genetic Disorders
  • Figure 8.7: Purpose of Opting for Genetic Counseling
  • Figure 8.8: Reasons for Opting for Genetic Counseling
  • Figure 8.9: Essential Components of Genetic Counseling
  • Figure 8.10: Types of Genetic Counseling Services
  • Figure 9.1: Recent Collaborations in NIPT: Distribution by Year
  • Figure 9.2: Recent Collaborations in NIPT: Distribution by Type of Model
  • Figure 9.3: Recent Collaborations in NIPT: Most Active Players
  • Figure 9.4: Recent Collaborations in Newborn Screening: Distribution by Year
  • Figure 9.5: Recent Collaborations in Newborn Screening: Distribution by Type of Model
  • Figure 9.6: Recent Collaborations in Newborn Screening: Most Active Players
  • Figure 10.1: NIPT Market (2017-2027): Base Scenario (USD Billion)
  • Figure 10.2: NIPT Market (2017-2027): Distribution by Patient Risk Group, Base Scenario (USD Billion)
  • Figure 10.3: NIPT Market: Share by Patient Risk Groups, 2017, 2027 (USD Billion, %)
  • Figure 10.4: NIPT Market (2017-2027): Distribution by Geography, Base Scenario (USD Billion)
  • Figure 10.5: NIPT Market (2017-2027): Distribution by Geography, Base Scenario (Test Volume, Million)
  • Figure 10.6: NIPT Market: Share by Geography, 2017, 2027 (%)
  • Figure 10.7: NIPT Market in North America (2017-2027): Base Scenario (USD Billion)
  • Figure 10.8: NIPT Market in North America (2017-2027): Base Scenario (Test Volume, Million)
  • Figure 10.9: NIPT Market in Europe (2017-2027): Base Scenario (USD Billion)
  • Figure 10.10: NIPT Market in Europe (2017-2027): Base Scenario (Test Volume, Million)
  • Figure 10.11: NIPT Market in Asia (2017-2027): Base Scenario (USD Billion)
  • Figure 10.12: NIPT Market in Asia (2017-2027): Base Scenario (Test Volume, Million)
  • Figure 10.13: NIPT Market in Rest of the World (2017-2027): Base Scenario (USD Billion)
  • Figure 10.14: NIPT Market in Rest of the World (2017-2027): Base Scenario (Test Volume, Million)
  • Figure 10.15: NIPT Market: Share by Indication, 2017, 2027 (%)
  • Figure 10.16: NIPT Market: Share by Stage of Pregnancy, 2027 (%)
  • Figure 10.17: NIPT Market: Share by Individual NIPTs, 2017 (%)
  • Figure 11.1: Overall NIPT Market (USD Billion), 2017, 2022 and 2027
  • Figure 13.1: Survey Analysis: Distribution by Type of Company
  • Figure 13.2: Survey Analysis: Distribution by Location of Respondents
  • Figure 13.3: Survey Analysis: Distribution by Seniority Level of Respondents
  • Figure 13.4: Survey Analysis: Distribution by Focus Area of the Company
  • Figure 13.5: Survey Analysis: Distribution by Type of Lead Products(s)
  • Figure 13.6: Survey Analysis: Distribution by Purpose of Lead Product(s)
  • Figure 13.7: Survey Analysis: Distribution by Commercial Availability of Lead Product(s)
  • Figure 13.8: Survey Analysis: Distribution by Likely Market Size of Prenatal Testing
  • Figure 13.9: Survey Analysis: Distribution by Likely Market Size of Newborn Screening

List of Tables:

  • Table 3.1: Differences Between Screening and Diagnostic Tests
  • Table 3.2: Common Disorders: Annual Cost of Treatment
  • Table 3.3: Common Genetic Disorders: Causes and Symptoms
  • Table 3.4: Prenatal Testing: Invasive and Non-Invasive Methods
  • Table 3.5: Test Combinations in Triple and Quadruple Screen
  • Table 3.6: Triple Screen Assay: Abnormal Levels of Markers in Different Disorders
  • Table 3.7: Prenatal Screening Tests: Risk Assessment Strategies
  • Table 4.1: NIPTs: Development Landscape
  • Table 4.2: NIPT: Comparison of Sequencing based Technology Platforms
  • Table 4.3: NIPT: Technology Platforms
  • Table 4.4: Prenatal Testing: Other Initiatives
  • Table 4.5: Newborn Screening Tests: Development Landscape
  • Table 4.6: Newborn Screening: Other Initiatives
  • Table 5.1: NIPTs: Distribution by Geographical Coverage
  • Table 5.2: Heat Map Analysis: Scoring Criteria
  • Table 5.3: Commercialized NIPTs: A Competitive Heat Map Analysis
  • Table 5.4: Harvey Ball Analysis: Evaluation Criteria
  • Table 5.5: NIPT Harvey Ball Analysis: Distribution by Indications Screened Under Test Panel
  • Table 6.1: Ariosa Diagnostics: List of Funding Instances and Investors
  • Table 6.2: Harmony® Test: Launch Details for Different Geographies
  • Table 6.3: Harmony® Test: Published Studies
  • Table 6.4: Harmony® and Traditional Screening Methods: Comparison of Clinical Performance
  • Table 6.5: Harmony® Test: Comparison of Clinical Performance for Tested Indications
  • Table 6.6: Harmony® Test: Comparison of PPV in Different Patient Cohorts
  • Table 6.7: BGI: List of Funding Instances and Investors
  • Table 6.8: NIFTY® Test: Launch Details for Different Geographies
  • Table 6.9: Common NIPT Tests: Comparative Performance Evaluation
  • Table 6.10: NIFTY® and Traditional Screening Methods: Comparison of Clinical Performance
  • Table 6.11: NIFTY® Test: Published Studies
  • Table 6.12: NIFTY® Test: Comparison of Test Performance for the Tested Indications
  • Table 6.13: Natera®: List of Funding Instances and Investors
  • Table 6.14: Natera®: Summary of Marketed Products
  • Table 6.15: Panorama® Test: Launch Details for Different Geographies
  • Table 6.16: Panorama® Test: Available Options and Cost Details
  • Table 6.17: Panorama® Test: Comparison of PPV in Different Patient Cohorts
  • Table 6.18: Panorama® and Traditional Screening Methods: Comparison of Clinical Performance
  • Table 6.19: Panorama® Test: Comparison of Clinical Performance for Tested Indications
  • Table 6.20: Panorama® Test: Ongoing Clinical Trials
  • Table 6.21: SequenomTM NIPTs: Launch Details for Different Geographies
  • Table 6.22: SequenomTM: List of Funding Instances and Investors
  • Table 6.23: SequenomTM: Product Details
  • Table 6.24: MaterniT® GENOME Test: Comparison with Fetal Karyotype Test
  • Table 6.25: MaterniT® GENOME Test: Comparison of Clinical Performance for Tested Indications
  • Table 6.26: MaterniT® GENOME Test: Reasons for Increase in Clinical Uptake
  • Table 6.27: VisibiliTTM Test: Comparison of Clinical Performance for Tested Indications
  • Table 6.28: MaterniT21® PLUS Test: Published Studies
  • Table 6.29: NextViewTM Array Diagnostic Test Platform: Panel Options
  • Table 6.30: Illumina®: Regional Laboratory Partners for Verifi® Prenatal Test
  • Table 6.31: Verinata Health: List of Funding Instances and Investors
  • Table 6.32: Verifi® Prenatal Test: Launch Details for Different Geographies
  • Table 6.33: Verifi® Prenatal Test: Comparison of Clinical Performance for Tested Indications
  • Table 6.34: Popular NIPTs: A Detailed Comparision
  • Table 7.1: Traditional and Next-Generation Newborn Screening: Comparison
  • Table 7.2: Newborn Screening: List of Companies Profiled
  • Table 7.3: NOVATM Newborn Genetic Test: Clinical Performance Validation
  • Table 7.4: Cordlife Group: List of Funding Instances and Investors
  • Table 7.5: MetaScreenTM Testing Platforms: A Detailed Comparison
  • Table 7.6: MetaScreenTM: Available Options
  • Table 7.7: Parabase Genomics: List of Funding Instances and Investors
  • Table 7.8: PerkinElmer® Diagnostics Segment: Product Details
  • Table 7.9: PerkinElmer® Genetics: Available Products and Cost Details
  • Table 7.10: AB SCIEX: Company Profile
  • Table 7.11: Aegis Sciences: Company Profile
  • Table 7.12: ARCHIMEDlife: Company Profile
  • Table 7.13: Baby Genes: Company Profile
  • Table 7.14: CENTOGENE: Company Profile
  • Table 7.15: EGL Genetic Diagnostics: Company Profile
  • Table 7.16: GeneTech: Company Profile
  • Table 7.17: iLife Discoveries: Company Profile
  • Table 7.18: Macrogen: Company Profile
  • Table 7.19: MapmygenomeTM: Company Profile
  • Table 7.20: Navigene Genetic Science: Company Profile
  • Table 7.21: NeoGen Labs: Company Profile
  • Table 7.22: Next Biosciences: Company Profile
  • Table 7.23: NIMGenetics: Company Profile
  • Table 7.24: Pediatrix Medical Group: Company Profile
  • Table 7.25: PreventiNe Life Care: Company Profile
  • Table 7.26: Synapse Diagnostics: Company Profile
  • Table 7.27: Trivitron Healthcare: Company Profile
  • Table 7.28: Recommended Uniform Screening Panel (RUSP): Core and Secondary Disorders
  • Table 8.1: Carrier Testing: Most Prominent Disorders
  • Table 8.2: Carrier Testing / Preconception Care: Commercialized Tests
  • Table 8.3: PGD / PGS: Commercialized Tests
  • Table 9.1: NIPT: Recent Collaborations (2011-2017)
  • Table 9.2: Newborn Screening: Recent Collaborations (2011-2017)
  • Table 10.1: NIPT Forecast Assumptions: Patient Population
  • Table 10.2: NIPT Forecast Assumptions: Price Estimation
  • Table 10.3: NIPT Forecast Assumptions: Adoption Rates and Geographical Trends
  • Table 10.4: Newborn Screening: Opportunity Analysis, 2017-2027
  • Table 13.1: Survey Response: Overview of the Participating Companies
  • Table 13.2: Survey Response: Seniority Level of Respondents
  • Table 13.3: Survey Response: Focus Area of the Company
  • Table 13.4: Survey Response: Type of Lead Product(s)
  • Table 13.5: Survey Response: Purpose of Lead Product(s)
  • Table 13.6: Survey Response: Commercial Availability of Lead Product(s)
  • Table 13.7: Survey Response: Likely Market Size
  • Table 14.1: Chromosomal Abnormalities: Distribution by Type
  • Table 14.2: Common Causes of Deaths in Newborns
  • Table 14.3: NIPT: Distribution by Stage of Development
  • Table 14.4: NIPT: Distribution by Technology Platform
  • Table 14.5: NIPT: Distribution by Type of Indications
  • Table 14.6: NIPT: Distribution by Chromosomal Abnormalities
  • Table 14.7: NIPT: Distribution by Sex Chromosomal Abnormalities
  • Table 14.8: NIPT: Distribution by Microdeletion Syndromes
  • Table 14.9: NIPT: Distribution by Stage of Pregnancy
  • Table 14.10: NIPT: Distribution by Result Turnaround Time
  • Table 14.11: Newborn Screening: Distribution by Screening Type
  • Table 14.12: Newborn Screening: Distribution by Technology Platforms
  • Table 14.13: Newborn Screening: Distribution by Type of Indications
  • Table 14.14: Newborn Screening: Distribution by Screening Type on the Basis of Period of Sample Collection After Birth
  • Table 14.15: Newborn Screening: Distribution by Result Turnaround Time
  • Table 14.16: Natera®: Annual Revenues, 2013-Q1 2017 (USD Million)
  • Table 14.17: SequenomTM: Annual Revenues, 2011-Q1 2016 (USD Million)
  • Table 14.18: Cordlife Group: Annual Revenues, 2012-2016 (USD Million)
  • Table 14.19: PerkinElmer®: Annual Revenues, 2012-Q1 2017 (USD Million)
  • Table 14.20: Recent Collaborations in NIPT: Distribution by Year
  • Table 14.21: Recent Collaborations in NIPT: Distribution by Type of Model
  • Table 14.22: Recent Collaborations in NIPT: Most Active Players
  • Table 14.23: Recent Collaborations in Newborn Screening: Distribution by Year
  • Table 14.24: Recent Collaborations in Newborn Screening: Distribution by Type of Model
  • Table 14.25: Recent Collaborations in Newborn Screening: Most Active Players
  • Table 14.26: NIPT Market: Distribution by Patient Population into Risk Groups
  • Table 14.27: NIPT Market (2017-2027): Base Scenario (USD Billion)
  • Table 14.28: NIPT Market (2017-2027): Optimistic Scenario (USD Billion)
  • Table 14.29: NIPT Market (2017-2027): Conservative Scenario (USD Billion)
  • Table 14.30: NIPT Market (2017-2027): Distribution by Patient Risk Group, Base Scenario (USD Billion)
  • Table 14.31: NIPT Market (2017-2027): Distribution by Patient Risk Group, Optimistic Scenario (USD Billion)
  • Table 14.32: NIPT Market (2017-2027): Distribution by Patient Risk Group, Conservative Scenario (USD Billion)
  • Table 14.33: NIPT Market: Share by Patient Risk Group, 2017, 2027 (USD Billion, %)
  • Table 14.34: NIPT Market (2017-2027): Distribution by Geography, Base Scenario (USD Billion)
  • Table 14.35: NIPT Market (2017-2027): Distribution by Geography, Optimistic Scenario (USD Billion)
  • Table 14.36: NIPT Market (2017-2027): Distribution by Geography, Conservative Scenario (USD Billion)
  • Table 14.37: NIPT Market (2017-2027): Distribution by Geography, Base Scenario (Test Volume, Million)
  • Table 14.38: NIPT Market (2017-2027): Distribution by Geography, Optimistic Scenario (Test Volume, Million)
  • Table 14.39: NIPT Market (2017-2027): Distribution by Geography, Conservative Scenario (Test Volume, Million)
  • Table 14.40: NIPT Market: Share by Geography, 2017, 2027 (%)
  • Table 14.41: NIPT Market in North America (2017-2027): Base Scenario (USD Billion)
  • Table 14.42: NIPT Market in North America (2017-2027): Optimistic Scenario (USD Billion)
  • Table 14.43: NIPT Market in North America (2017-2027): Conservative Scenario (USD Billion)
  • Table 14.44: NIPT Market in North America (2017-2027): Base Scenario (Test Volume, Million)
  • Table 14.45: NIPT Market in North America (2017-2027): Optimistic Scenario (Test Volume, Million)
  • Table 14.46: NIPT Market in North America (2017-2027): Conservative Scenario (Test Volume, Million)
  • Table 14.47: NIPT Market in Europe (2017-2027): Base Scenario (USD Billion)
  • Table 14.48: NIPT Market in Europe (2017-2027): Optimistic Scenario (USD Billion)
  • Table 14.49: NIPT Market in Europe (2017-2027): Conservative Scenario (USD Billion)
  • Table 14.50: NIPT Market in Europe (2017-2027): Base Scenario (Test Volume, Million)
  • Table 14.51: NIPT Market in Europe (2017-2027): Optimistic Scenario (Test Volume, Million)
  • Table 14.52: NIPT Market in Europe (2017-2027): Conservative Scenario (Test Volume, Million)
  • Table 14.53: NIPT Market in Asia (2017-2027): Base Scenario (USD Billion)
  • Table 14.54: NIPT Market in Asia (2017-2027): Optimistic Scenario (USD Billion)
  • Table 14.55: NIPT Market in Asia (2017-2027): Conservative Scenario (USD Billion)
  • Table 14.56: NIPT Market in Asia (2017-2027): Base Scenario (Test Volume, Million)
  • Table 14.57: NIPT Market in Asia (2017-2027): Optimistic Scenario (Test Volume, Million)
  • Table 14.58: NIPT Market in Asia (2017-2027): Conservative Scenario (Test Volume, Million)
  • Table 14.59: NIPT Market in Rest of the World (2017-2027): Base Scenario (USD Billion)
  • Table 14.60: NIPT Market in Rest of the World (2017-2027): Optimistic Scenario (USD Billion)
  • Table 14.61: NIPT Market in Rest of the World (2017-2027): Conservative Scenario (USD Billion)
  • Table 14.62: NIPT Market in Rest of the World (2017-2027): Base Scenario (Test Volume, Million)
  • Table 14.63: NIPT Market in Rest of the World (2017-2027): Optimistic Scenario (Test Volume, Million)
  • Table 14.64: NIPT Market in Rest of the World (2017-2027): Conservative Scenario (Test Volume, Million)
  • Table 14.65: NIPT Market: Share by Indication, 2017, 2027 (%)
  • Table 14.66: NIPT Market: Share by Stage of Pregnancy, 2017 (%)
  • Table 14.67: NIPT Market: Share by Individual NIPTs, 2017 (%)
  • Table 14.68: Overall NIPT Market Summary (USD Billion): 2017, 2022 and 2027
  • Table 14.69: Survey Analysis: Distribution by Type of Company
  • Table 14.70: Survey Analysis: Distribution by Location of Respondents
  • Table 14.71: Survey Analysis: Distribution by Seniority Level of Respondents
  • Table 14.72: Survey Analysis: Distribution by Focus Area of the Company
  • Table 14.73: Survey Analysis: Distribution by Lead Product(s)
  • Table 14.74: Survey Analysis: Distribution by Purpose of Lead Product(s)
  • Table 14.75: Survey Analysis: Distribution by Commercial Availability of Lead Product(s)
  • Table 14.76: Survey Analysis: Distribution by Likely Market Size of Prenatal Testing
  • Table 14.77: Survey Analysis: Distribution by Likely Market Size of Newborn Screening

Listed Companies:

  • 1. 23andMe
  • 2. A*STAR's Institute of Microelectronics (IME)
  • 3. AB SCIEX
  • 4. Abbott Molecular
  • 5. Abbott Pathology
  • 6. Academy of Finland
  • 7. Accela
  • 8. Acibadem Healthcare Group
  • 9. American College of Medical Genetics and Genomics (ACMG)
  • 10. American Congress of Obstetrics and Gynecology (ACOG)
  • 11. Adgenix
  • 12. Advance Medical
  • 13. Advanced Liquid Logic
  • 14. Aegis Sciences
  • 15. Aetna
  • 16. Affymetrix
  • 17. Agena Bioscience
  • 18. Agilent Technologies
  • 19. AL Borg Medical Laboratories
  • 20. Alafi Capital
  • 21. Alloy Ventures
  • 22. Alpert Medical School, Brown University
  • 23. Amarey Nova Medical Group
  • 24. Amedes
  • 25. American Association for Laboratory Accreditation (A2LA)
  • 26. American Association of Blood Banks (AABB)
  • 27. American Clinical Laboratory Association (ACLA)
  • 28. American Medical Association (AMA)
  • 29. American Hospital of Paris
  • 30. Ani Biotech
  • 31. Ani Labsystems
  • 32. Annoroad Gene Technology
  • 33. Anthem Blue Cross and Blue Shield
  • 34. Antisel
  • 35. APHL - Association of Public Health Laboratories
  • 36. Applied Spectral Imaging (ASI)
  • 37. Arabian Genetic Testing Company (AGTC)
  • 38. ARCEDI Biotech
  • 39. ARCHIMEDlife
  • 40. Ariosa Diagnostics
  • 41. ARUP Laboratories
  • 42. Asia Pacific Capital Management
  • 43. Asper Biotech
  • 44. Astoria-Pacific
  • 45. Atlas Genomics
  • 46. Australian Clinical Lab
  • 47. AutoGenomics
  • 48. Baby Genes
  • 49. Baebies
  • 50. Bangkok Cytogenetics Center
  • 51. Bangkok R.I.A LAB
  • 52. Basetra
  • 53. Baylor Genetics
  • 54. BEAZ
  • 55. Berry Genomics
  • 56. BGI
  • 57. BGI Agriculture
  • 58. BGI College
  • 59. BGI Diagnosis
  • 60. BGI Forensics
  • 61. BGI Genomics
  • 62. BGI Health
  • 63. BGI Manufacturing
  • 64. BGI Research
  • 65. BGI Tech
  • 66. Big Belli
  • 67. BioGen Medical
  • 68. Biomnis
  • 69. BioPoint
  • 70. Bio-Rad Laboratories
  • 71. BioReference Laboratories
  • 72. Bioscience Genomics
  • 73. Bioscience Institute
  • 74. Birmingham Women's Hospital
  • 75. BlueGenome
  • 76. Bome Sanayi Ürünleri Dis Ticaret
  • 77. Brown University
  • 78. CairoGene
  • 79. California Department of Health
  • 80. CAPP Medical
  • 81. Catholic Health Initiatives (CHI)
  • 82. Cell Genetics
  • 83. CellScape
  • 84. Cenata
  • 85. Center for Human Genetics and Laboratory Diagnostics
  • 86. Center for Medical Genetics, Houston
  • 87. Center for Medical Genomics (CMG)
  • 88. Centers for Disease Control and Prevention (CDC)
  • 89. Centers for Medicare and Medicaid Services (CMS)
  • 90. CENTOGENE
  • 91. CENTOGENE ARABIA
  • 92. Centrum Badan DNA Group
  • 93. CGC Genetics
  • 94. Children's Mercy Hospital, Kansas
  • 95. China National GeneBank
  • 96. China's National Health and Family Planning Commission
  • 97. Chinese Food and Drug Administration
  • 98. Cigna
  • 99. Cinven
  • 100. Claremont Creek Ventures
  • 101. Clarity Medical Systems
  • 102. CML Healthcare Collection Centers
  • 103. CMS Computers
  • 104. Coalition for Access to Prenatal Screening (CAPS)
  • 105. College of American Pathologists (CAP)
  • 106. Color Genomics
  • 107. CombiMatrix
  • 108. Commission for Office Laboratory Accreditation
  • 109. Complete Genomics
  • 110. Cooper SurgicalTM
  • 111. CooperGenomics
  • 112. Cordlife Group
  • 113. Cordlife Sciences
  • 114. Council of Regional Networks for Genetic Services
  • 115. Counsyl
  • 116. Cypher Genomics
  • 117. Cyprus Institute of Neurology and Genetics
  • 118. Cytogenomic External Quality Assessment Service (CEQAS)
  • 119. DaAn Gene
  • 120. Danaher Corporation
  • 121. DASA Group
  • 122. Datar Genetics
  • 123. DBS Systems
  • 124. deCODEme genetics
  • 125. Department of Health and Human Services (HHS), US
  • 126. Devyser
  • 127. DiagCor
  • 128. Diputación de Bizkaia
  • 129. DNA Diagnostics Center (DDC)
  • 130. Domain Associates
  • 131. Dorevitch Pathology
  • 132. Douglass Hanly Moir Pathology
  • 133. Dr Lal PathLabs
  • 134. DrGene
  • 135. Eastern Biotech & Life Sciences
  • 136. Echevarne
  • 137. EGL Genetic Diagnostics
  • 138. ELAN Group
  • 139. ELIPS
  • 140. Elite PharmaLab Solutions
  • 141. Elucigene Diagnostics
  • 142. Emory Genetic Diagnostics
  • 143. Emory University's School of Medicine
  • 144. Empireo Molecular Diagnostic
  • 145. Eone Life Science Institute and Diagnomics
  • 146. EONE-DIAGNOMICS Genome Center (EDGC)
  • 147. ePlanet Ventures
  • 148. ESPERITE
  • 149. Eurofins Clinical Genetics India (ECGI)
  • 150. Eurofins Scientific
  • 151. European Diagnostics Services Group
  • 152. European Molecular Genetics Quality Network (EMQN)
  • 153. EvolveGene®
  • 154. Famina Healthcare
  • 155. FASTERIS
  • 156. Food and Drug Administration (FDA)
  • 157. Fetal Medicine Foundation
  • 158. Fidelity Growth
  • 159. Finnish Funding Agency for Innovations
  • 160. Flatiron Health
  • 161. Fleury Medicina e Saúde (Fleury Group)
  • 162. Florida Agency for Health Care and Administration
  • 163. Foundation for the Accreditation of Cellular Therapy (FACT)
  • 164. Foundation Medicine
  • 165. Founders Fund
  • 166. Franklin Templeton Investments
  • 167. Federal Trade Commission (FTC)
  • 168. GATC Biotech
  • 169. GENDIA (GENetic DIAgnostic Network)
  • 170. Gene by Gene
  • 171. GeneDx
  • 172. GeneMetrics
  • 173. Geneplus
  • 174. GeneProof
  • 175. Genesis GeneticsTM
  • 176. Genesis GeneticsTM South Africa
  • 177. GeneSupport
  • 178. Genetadi Biotech
  • 179. GeneTech
  • 180. GeneTech Kazusa Laboratory
  • 181. Genetic Associates
  • 182. Genesis Genetics International
  • 183. GeNext
  • 184. Genia Technologies
  • 185. GENNET
  • 186. Genoks
  • 187. GenoLogics Life Sciences Software
  • 188. Genoma
  • 189. Genomed
  • 190. Genomic Diagnostics
  • 191. Genomics For life
  • 192. Genomi-k
  • 193. Genomill Health
  • 194. GenomixLAB
  • 195. Genopharm
  • 196. Genos
  • 197. GenPath Diagnostics
  • 198. Genpharm Services
  • 199. Gentica
  • 200. GENYCA
  • 201. GigaScience
  • 202. GN Otometrics
  • 203. Good Start Genetics
  • 204. Google India
  • 205. GRAIL
  • 206. GTL DNA
  • 207. Harmony Partners
  • 208. Headland Capital
  • 209. Health Professional Council of South Africa (HPCSA)
  • 210. Health Resources and Services Administration (HRSA)
  • 211. HealthCor Partners
  • 212. Helicos BioSciences
  • 213. Helix Holdings
  • 214. HemaXis
  • 215. HemoFlux
  • 216. Henry Schein Medical
  • 217. Hitech Diagnostic Centre
  • 218. Hive Technologies
  • 219. Hologic
  • 220. Hong Kong Molecular Pathology Diagnostic Centre
  • 221. Hong Kong Screening Centre
  • 222. Hospital Israelita Albert Einstein
  • 223. Humana
  • 224. IBL International
  • 225. Icahn School of Medicine at Mount Sinai
  • 226. Integrated Gulf Biosystems
  • 227. iGene Diagnostics
  • 228. IGENOMIX
  • 229. Igentify
  • 230. iLife Discoveries
  • 231. Illumina®
  • 232. IMUA Family Services
  • 233. India Value Fund Advisors (IVFA)
  • 234. Indian Department of Biotechnology
  • 235. INEX (Innovations Exchange)
  • 236. InKaryo
  • 237. Innermost Healthcare
  • 238. Innovation Elite
  • 239. Inova Translational Medical Institute
  • 240. Inqaba Biotec
  • 241. Insight Medical Genetics
  • 242. Institute of Medical Genetics, College of Life Science, Sichuan University
  • 243. Integrated Genetics
  • 244. Intercare Salubrity
  • 245. International 22q11.2 Foundation
  • 246. InterWest Health
  • 247. Invitae
  • 248. IQuum
  • 249. Isis Innovation
  • 250. International Society for Prenatal Diagnosis (ISPD)
  • 251. Istenhegyi Centre for Genetic Diagnostics
  • 252. IVF Michigan
  • 253. IVIOMICS
  • 254. Jennison Associates
  • 255. Joaquim Chaves Group
  • 256. Joint Commission on Accreditation of Healthcare Organizations
  • 257. Just4Me Genetics
  • 258. K3
  • 259. Kalorama Information
  • 260. Kansas City School of Medicine, University of Missouri
  • 261. Kapa Biosystems and Signature Diagnostics
  • 262. KellBenx
  • 263. Knome
  • 264. Knox Audiology
  • 265. LABCO Quality Diagnostics
  • 266. Laboratoire Cerba
  • 267. Laboratory Corporation of America® Holding
  • 268. LaboSud
  • 269. Labsystems Diagnostics
  • 270. Laverty Pathology
  • 271. Li Ka Shing Institute of Health Sciences
  • 272. Life TechnologiesTM
  • 273. LifeCodexx
  • 274. LifeGlobal Group
  • 275. LifeLabs Genetics
  • 276. Lightspeed Venture Partners
  • 277. Lilac Insights
  • 278. Macrogen
  • 279. Magee-Women's Hospital of UPMC Center for Medical Genetics
  • 280. Mahidol University
  • 281. MAICO Diagnostics
  • 282. Malaysia Fetal Genome
  • 283. MAP Diagnostics
  • 284. Mapmygenome™
  • 285. Maryland Department of Health and Mental Hygiene
  • 286. Masimo® Corporation
  • 287. Maternal and Child Health Bureau (MCHB)
  • 288. Maverix Biomics
  • 289. Mayo Medical Laboratories
  • 290. McKesson Medical-Surgical
  • 291. MedGen
  • 292. MedGenome
  • 293. Medical Chambers Kensington
  • 294. Medical Genetics Laboratory, Baylor College of Medicine
  • 295. Medical Genomics
  • 296. Medisupport
  • 297. MedLab Asia Group
  • 298. MEDNAX
  • 299. Meritech Capital Partners
  • 300. Metis Genetics
  • 301. Metropolis
  • 302. Ministry of Science and Technology, India
  • 303. MIT Angels
  • 304. Mohr Davidow Ventures
  • 305. Molecular Devices
  • 306. Monobind
  • 307. MOR Institute for Medical Data
  • 308. Mount Sinai Genetic Testing Laboratory
  • 309. MSA Safety
  • 310. MultiCare
  • 311. Multigene Diagnostics
  • 312. MultiPlan
  • 313. Multiplicom
  • 314. Murdoch Children's Research Institute
  • 315. MyGenetx
  • 316. MyMedLab
  • 317. Myraqa
  • 318. National Accreditation Board for Testing and Calibration Laboratories (NABL)
  • 319. Natera®
  • 320. National Health and Family Planning Commission (NHFPC)
  • 321. National Institutes of Health (NIH)
  • 322. National Newborn Bloodspot Screening Laboratory (NNBSL), Temple Street Children's University Hospital
  • 323. National Society of Genetic Counselors
  • 324. National University of Singapore (NUS)
  • 325. Natus® Medical
  • 326. Navigene Genetic Science
  • 327. NeoGen Labs
  • 328. NEUROSPEC
  • 329. New Born Solutions
  • 330. New York Department of Health
  • 331. New York State Laboratory
  • 332. Newborn Foundation
  • 333. NewBorn Gene ID
  • 334. NewBridge Pharmaceuticals
  • 335. Next Biosciences
  • 336. NextBio
  • 337. NextlineTM Diagnostics
  • 338. NicView
  • 339. NIMGenetics
  • 340. NIPD Genetics
  • 341. North-West University
  • 342. Novogene
  • 343. NX Prenatal
  • 344. NxGen MDx
  • 345. Onsite Neonatal Partners
  • 346. OPKO Health
  • 347. OrbiMed
  • 348. Otometrics
  • 349. Oxford Biosystems
  • 350. Oxford Gene Technology (OGT)
  • 351. OZ Systems
  • 352. PacGenomics
  • 353. Pacific Rim Pathology
  • 354. Padtan
  • 355. Paperboy Ventures
  • 356. Parabase Genomics
  • 357. Paragon Genomics
  • 358. Pathology Associates Medical Laboratories (PAML)
  • 359. Pathway Genomics
  • 360. Pediatrix Medical Group
  • 361. Pennsylvania Department of Health
  • 362. Perinatal Quality Foundation (PQF)
  • 363. PerkinElmer® Genetics
  • 364. Personal Genomics
  • 365. Phoebus Genetics
  • 366. Pink Newborn Services
  • 367. PlexBio
  • 368. Positive Bioscience
  • 369. Postnatal Peace
  • 370. Pregnicare
  • 371. Premaitha Health
  • 372. Prenatal Diagnosis Centers (PDC)
  • 373. Prenatal Genetics
  • 374. Prenetics
  • 375. Pressure BioSciences
  • 376. PreventiNe Life Care
  • 377. Previvo Genetics
  • 378. Primary Health Care
  • 379. Profema
  • 380. Progenesis
  • 381. Progenitest
  • 382. Progenity
  • 383. Pronto Diagnostics
  • 384. ProPath
  • 385. Providence Health & Services
  • 386. QML Pathology
  • 387. Quantum Diagnostics
  • 388. Quest Diagnostics
  • 389. RA Capital Management
  • 390. Ramathibodi Hospital, Thailand
  • 391. Rarecells
  • 392. Ravgen
  • 393. Recombine
  • 394. Red Rock Fertility Center
  • 395. Reproductive Genetic Innovations (RGI)
  • 396. Reprogenetics
  • 397. Rhode Island Department of Health
  • 398. Roche
  • 399. Rothschild Ventures Asia
  • 400. S.R.L
  • 401. Safembryo
  • 402. Sagentia
  • 403. Science Labs NIPT
  • 404. ScreenCell
  • 405. Sebia
  • 406. Secretary's Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC)
  • 407. Secuvita
  • 408. Sengenics
  • 409. Seoul National University Hospital (SNUH)
  • 410. SequenomTM
  • 411. Sequenom Center for Molecular Medicine (SCMM)
  • 412. Sequoia Capital
  • 413. SeraCare Life Sciences
  • 414. Servicios Genéticos OriGen
  • 415. Shenz Medical Center
  • 416. Shenzhen BGI Unicare Clinic
  • 417. Shenzhen Chi-Next Exchange
  • 418. Shimadzu Corporation
  • 419. Sichuan University
  • 420. Siemens
  • 421. Silicon Biosystems
  • 422. Singapore Angel Network
  • 423. Singlera Genomics
  • 424. Siriraj Hospital, Thailand
  • 425. Sistemas Genómicos
  • 426. SNPgenomics
  • 427. Sofinnova Ventures
  • 428. SOFIVA Genomics
  • 429. Solstas Lab Partners
  • 430. Sonic Healthcare
  • 431. Sophia Genetics
  • 432. Source BioScience
  • 433. SouthGenetics
  • 434. SpOtOn Clinical Diagnostics
  • 435. Srushti Hospital, India
  • 436. St. George's University
  • 437. St. George's Hospital
  • 438. Stanford University
  • 439. StartUp Health
  • 440. Sutter Hill Ventures
  • 441. Swiss Institute for Bioinformatics
  • 442. SXE Ventures
  • 443. Synapse Diagnostics
  • 444. SYNERGY Medical Systems
  • 445. SYNLAB
  • 446. Tasmanian Medical Laboratories
  • 447. TATAA Biocenter
  • 448. Teva Pharmaceutical
  • 449. Thailand Center of Excellence for Life Sciences (TCELS)
  • 450. The Chinese University of Hong Kong
  • 451. The Doctors Laboratory (TDL)
  • 452. The Fetal Medicine Centre, London
  • 453. The Society for Maternal-Fetal Medicine (SMFM)
  • 454. Thermo Fisher Scientific
  • 455. This Is My
  • 456. TMC Life Sciences
  • 457. TOMA Advanced Biomedical Assays
  • 458. Tor Vergata University, Rome
  • 459. Translational Health Science Technology Institute (THSTI)
  • 460. Trivitron Healthcare
  • 461. TrovaGene
  • 462. Tulip Diagnostics
  • 463. Tute Genomics
  • 464. UK Centre of Excellence
  • 465. UK NEQAS
  • 466. UNIConnect
  • 467. Unilabs
  • 468. United Overseas Bank Venture Management
  • 469. UnitedHealthcare
  • 470. University of Antwerp
  • 471. University of California
  • 472. University of Hong Kong
  • 473. University of Rochester
  • 474. University of Turku
  • 475. University of Washington
  • 476. Vanadis Diagnostics
  • 477. Vantari Genetics
  • 478. Venrock
  • 479. Verinata Health
  • 480. Victorian Clinical Genetics Services (VCGS)
  • 481. Viollier
  • 482. Virion-Serion
  • 483. Visional Medical
  • 484. Visunex Medical Systems
  • 485. Vivosonic
  • 486. Walnut Venture Associates
  • 487. West Midlands Regional Genetics Laboratory
  • 488. Western Diagnostic Pathology
  • 489. Wolfson Institute of Preventive Medicine
  • 490. Women and Infant's Hospital, Rhode Island
  • 491. World Health Organization (WHO)
  • 492. WuXi AppTec (WuXi Biologics)
  • 493. Xcelom
  • 494. Yale School of Medicine
  • 495. Yale Women and Children's Center
  • 496. Yikon Genomics
  • 497. Yourgene Bioscience
  • 498. ZenTec
Back to Top